Magnetic Resonance Spectroscopy in Myocardial Disease  by Hudsmith, Lucy E. & Neubauer, Stefan
SM
i
L
O
M
i
3
t
o
t
m
p
i
f
o
m
c
F
C
i
e
t
p
i
(
d
c
o
o
f
i
p
n
t
F
M
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 2 , N O . 1 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 0 8 . 0 8 . 0 0 5T A T E O F - T H E - A R T P A P E R
agnetic Resonance Spectroscopy
n Myocardial Disease
ucy E. Hudsmith, MA, MRCP, Stefan Neubauer, MD, FRCP
xford, United Kingdom
agnetic resonance spectroscopy (MRS) is the only noninvasive, nonradiation exposure technique for the
nvestigation of cardiac metabolism in vivo. MRS uses magnetic resonance signals from nuclei, such as
1phosphorus, 1hydrogen, and 23sodium, to provide comprehensivemetabolic and biochemical informa-
ion about cardiacmuscle. This method is highly versatile and can providemetabolic insights into the role
f cardiac metabolism, in particular, cardiac energetics, in a wide number of conditions, including hyper-
ensive, valvular, and ischemic heart disease, heart failure, and cardiac transplantation, as well as cardio-
yopathies. This method can also be used to monitor patient responses to therapeutic interventions:
harmacologic, surgical, or interventional. When combined with cardiovascular magnetic resonance
maging,MRS enables detailed pathophysiologic insights into the inter-relations among cardiac structure,
unction, perfusion, andmetabolism. However, MRS is currently used primarily as a research tool because
f low temporal and spatial resolution and low reproducibility. It is hoped that future technical develop-
ents and use of higher magnetic field strengths (such as 7-T) may enable application of cardiac MRS in
linical practice. (J Am Coll Cardiol Img 2009;2:87–96) © 2009 by the American College of Cardiology
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Hosardiovascular magnetic resonance (CMR)
s a widespread imaging technique, used
xtensively in clinical cardiology, which uses
he nuclear spin of protons in fat and water to
rovide detailed anatomical and functional
mages. Magnetic resonance spectroscopy
MRS) is the only noninvasive imaging mo-
ality that provides insight into metabolic
omponents of cardiac muscle in vivo with-
ut the use of an external tracer. MRS not
nly detects signal from protons, but also
rom other nuclei with a nuclear spin includ-
ng 23sodium (Na), 13carbon (C), and 31phos-
horus (P). 1H-MRS allows detection of a
umber of metabolites, including total crea-
ine, lactate, deoxymyoglobin, and fatty ac-
rom the Department of Cardiovascular Medicine, John Radcliffe
anuscript received July 29, 2008; accepted August 6, 2008.ds; 31P-MRS enables detection of adenosine
riphosphate (ATP) and phosphocreatine;
3C assesses the metabolic pathways of gly-
olysis, the tricarboxylic acid cycle or beta-
xidation; and 23Na-magnetic resonance im-
ging (strictly speaking, not a spectroscopy
ethod, but listed here because it provides
iochemical information) allows detection of
yocardial tissue sodium content (1,2).
However, these nonproton nuclei have a
ignificantly lower magnetic resonance sensitiv-
ty than 1hydrogen (1H) and are present in
oncentrations 4 to 5 orders of magnitude
ower than those of 1H nuclei of water and fat.
s a result, the temporal and spatial resolution
f MRS severely limits its current clinical
pital, Oxford, United Kingdom.
a
r
w
s
q
a
s
o
a
t
i
H
T
i
m
g
C
a
t
s
s
s
s
o
o
m
p
a
f
m
n
t
q
s
f
a
t
t
r
A
t
q
w
s
f
c
q
a
m
g
s
g
d
p
l
r
h
e
t
d
A
W
(
l
P
C
t
n
t
f
m
v
f
M
v
i
A
A
A
C
C
r
H
c
M
s
N
A
3
m
s
P
a
3
chemical shift imaging
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 2 , N O . 1 , 2 0 0 9
J A N U A R Y 2 0 0 9 : 8 7 – 9 6
Neubauer and Hudsmith
MR Spectroscopy in Myocardial Disease
88pplication. Presently, MRS is technically difficult,
equires lengthy scans, and specialist expertise, as
ell as additional magnetic resonance hardware and
oftware. However, with improvement in data ac-
uisition and analysis techniques, many theoretical
nd clinical questions may be addressed and an-
wered by cardiac MRS.
The aim of this review is to provide an overview
f the principles of cardiac MRS and recent MRS
dvances, and to discuss clinical research applica-
ions of MRS in myocardial disease, particularly
schemic heart disease and heart failure.
uman Cardiac MRS
he majority of human cardiac MRS studies have
nvestigated the 31P nucleus. The first 31P-magnetic
resonance spectra from human myocar-
dium were obtained in the 1980s (3).
Cardiac MRS uses the same hardware as
CMR, for patients, typically a 1.5- or 3.0-T
magnet (ultra-field [7- to 18-T] for experi-
mental studies), with additional hardware
including nucleus-specific coils (e.g., 31P-
coil) and a broadband radiofrequency trans-
mitter to excite nonproton nuclei. Specific
MRS acquisition sequences, MRS post-
processing, and data analysis packages are
also required.
Subjects are studied in the prone posi-
tion to minimize the distance between the
surface coil and the heart and to minimize
respiratory motion. The magnetic reso-
nance spectrometer consists of a supercon-
ducting magnet interfaced with a com-
puter and a radiofrequency transmitter and
receiver (Fig. 1). Before acquisition, the
agnetic field must first be homogenized with shim
radients.
With the patient in the prone position, 1H
MR are first acquired to allow appropriate
natomical voxel selection for spectroscopic in-
errogation (Fig. 2). One of several localization
equences, such as depth-resolved surface coil
pectroscopy (DRESS), image-selected in vivo
pectroscopy (ISIS), or 3-dimensional chemical
hift imaging (3D-CSI), which enables selection
f multiple voxels in 3 dimensions, is required to
btain signal from a voxel positioned within the
yocardium excluding 31P signal from overlap-
ing skeletal muscle (4,5).
A radiofrequency pulse leads to spin excitation
ate
etic
-to-nd the resulting magnetic resonance signal, the cree induction decay (FID), is converted into a
agnetic resonance spectrum, which relates reso-
ance frequency to signal intensity, by Fourier
ransformation. A number of signal-averaged ac-
uisitions yield a magnetic resonance spectrum with
ufficient signal-to-noise ratio. Correction factors
or saturation and blood contamination are applied,
nd the area under each resonance is then propor-
ional to the amount of each 31P nucleus species in
he heart, allowing direct quantification of the
elative concentrations of each metabolite (2).
bsolute quantification of metabolite concentra-
ions, although preferable, is more complex, re-
uiring calibration of the 31P signal to the 1H
ater signal of the voxel (6). Another technique,
pectral localization with optimum pointspread
unction (SLOOP), enables interrogation of
urved voxels, shaped to the heart, and absolute
uantification using a 31P reference standard, flip
ngle calibration, B1 field mapping, and deter-
ination of myocardial mass within the interro-
ated voxel (7).
A typical 31P spectrum from a healthy subject
hows 6 resonances: 3 31P atoms (alpha, beta, and
amma) of ATP, phosphocreatine (PCr), 2.3-
iphosphoglycerate (from erythrocytes), and phos-
hodiesters (from membrane and serum phospho-
ipids) (Fig. 2).
Cardiac 31P-MRS, by means of the PCr-to-ATP
atio, provides an index of the energetic state of the
eart. The creatine kinase (CK) energy shuttle
nsures thermodynamic control of the cell, main-
aining a low concentration of free adenosine
iphosphate near the mitochondria, and providing
TP to the myofibrils for muscle contraction.
hen demand for ATP outweighs ATP synthesis
such as in ischemia), PCr levels fall, resulting in a
ow PCr-to-ATP ratio; ATP levels fall only when
Cr levels are substantially depleted, because the
K equilibrium constant strongly favors ATP syn-
hesis above PCr synthesis (8). A second mecha-
ism decreasing the PCr-to-ATP ratio is a reduc-
ion in the total creatine pool, as it occurs in heart
ailure.
At 1.5-T, required 31P-MRS voxels are 20 to 70
l, the acquisition time 20 to 40 min, yielding a
ariability of 15% for PCr-to-ATP ratios (9). These
actors are the major limitation of clinical cardiac
RS, and future developments and technical ad-
ances of MRS will have to deliver substantial
mprovements to make the method valuable forB B R E V I A T I O N S
N D A C R O N YM S
TP adenosine triphosph
K creatine kinase
MR cardiovascular magn
esonance imaging
CM hypertrophic
ardiomyopathy
RSmagnetic resonance
pectroscopy
YHA New York Heart
ssociation
1P-MRS 31phosphorus-
agnetic resonance
pectroscopy
Cr/ATP phosphocreatine
denosine triphosphate
D-CSI 3-dimensionallinical practice.
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89ther Nuclei
rotons (1H) have the highest MR sensitivity, so
H-MRS theoretically has the greatest potential for
linical application. 1H is present in a large number
f metabolites, including creatine, lactate, carnitine,
aurine, and the –CH3 and –CH2 resonances of
ipids. Measurement of total creatine, combined
ith 31P-MRS, allows noninvasive quantification of
denosine diphosphate and free energy change of
TP hydrolysis (10), and tissue deoxygenation can
e quantified using oxymyoglobin and deoxymyo-
lobin resonances (11). Current technical limita-
ions for 1H-MRS include the need to suppress the
trong water signal and the need for identification
f overlapping resonances.
At present, there are no clinical cardiac studies
sing 13C-MRS because of its low sensitivity and
Figure 1. Schematic Illustration of a Human Cardiac Magnetic R
The radiofrequency (RF) generator and workstation create an RF im
nuclear spins in the heart. The coil detects the RF response, which
Fourier transformation results in a magnetic resonance spectrum. R
Figure 2. 31P Magnetic Resonance Spectroscopy in a Healthy Vo
31P magnetic resonance spectrum using 3D chemical shift imaging
atoms of adenosine triphosphate (ATP) (alpha, beta, and gamma), p
phodiesters (PDE). 1H short-axis image showing localization of the v
mission, from Hudsmith and Neubauer (65).he requirement of exogenous 13C-labelled precur-
ors to detect a signal. However, in principle,
uantification of cardiac substrate use, the citric
cid cycle, and pyruvate dehydrogenase flux or
eta-oxidation of fatty acids may be possible, as has
een shown in experimental models (12,13).
23Na-magnetic resonance imaging can be used to
nvestigate and identify myocardial infarction and
iability (14). The total 23Na signal is elevated in
car and correlates with histologically identified
nfarct scar (see the following text).
linical CMR Spectroscopy Studies
he main clinical areas in which cardiac MRS may
rovide insight into pathophysiologic mechanisms
re ischemic heart disease, heart failure, transplan-
ation, and cardiomyopathies.
nance Spectroscopy Study
e, which is sent to the nucleus-speciﬁc RF coil to excite the
layed to the computer and stored as the free induction decay.
nted, with permission, from Hudsmith and Neubauer (65).
teer
healthy volunteer. The 6 resonances correspond to the 3 31P
phocreatine (PCr), 2,3-diphosphoglycerate (2,3-DPG), and phos-
l in the myocardial interventricular septum. Reprinted, with per-eso
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90Using 31P-MRS, the cardiac PCr-to-ATP ratios
f healthy subjects range between 1.1 and 2.5, with
ome evidence for a decrease in high-energy phos-
hates with increasing age (4,15,16). This large
ariation reflects methodologic variation of acquisi-
ion and analysis techniques, emphasizing the need
or development and standardization of these
echniques.
In normal volunteers as well as in athletes’ hearts
rowers and cyclists), PCr-to-ATP ratios remain
onstant except under extreme pharmacologic stim-
lation, when there is a modest reduction (17). In
ontrast, hypertensive patients with pathological
ypertrophy have reduced PCr-to-ATP ratios at
est and during pharmacologic stimulation, with
hese values correlating inversely with parameters of
iastolic function (18). 31P-MRS therefore provides
nsight into cardiac energy metabolism differences
n pathological and physiological hypertrophy and
ay, in the future, provide a method to differentiate
hese when screening athletes before competitive
election.
schemic Heart Disease
dentification of the metabolic changes in normally
erfused, ischemic, or scarred myocardium, com-
ining stress testing with 31P-MRS is a potentially
owerful tool to assess exercise-induced regional
schemia without the need for contrast agents or
adiation. Within seconds of reduced oxygenation,
Cr levels fall and inorganic phosphate levels in-
rease (19). The feasibility of detecting this clini-
ally has been shown by Weiss et al (20), who
emonstrated that in patients with 70% stenosis
f the left anterior descending coronary artery,
Cr-to-ATP ratios were normal at rest, signifi-
antly decreased from 1.5  0.3 to 0.9 0.2, with
30% to 35% increase in cardiac work with hand-
rip exercise, and then returned to 1.27 0.38 after
ecovery. After revascularization, PCr-to-ATP ra-
ios remained stable during the repeated exercise.
Buchthal et al. (21) and Johnson et al. (22) showed
hat myocardial PCr-to-ATP ratios decreased by 25
15% with hand grip exercise in females with
hest pain and normal luminal coronary arteries,
nd at 3-year follow-up, an initially abnormal 31P-
RS stress test was a strong predictor of future
ardiovascular events. These findings suggest mi-
rovascular dysfunction and tissue ischemia as
echanisms for chest pain in this patient cohort.
Thus, 31P-MRS stress testing might prove to be
valuable technique for investigating myocardial tschemia, monitoring response to interventional or
edical therapies, and being a prognostic tool.
owever, ischemic heart disease is spatially heter-
genous, requiring high spatial resolution of signal
cquisition, and the low resolution and high mea-
urement variability of MRS currently limits its
alue for regional assessment of ischemia in indi-
idual patients.
Cardiac 31P spectroscopy can identify viable
stunned or hibernating myocardium in which ATP
evels remain near normal [23]); in nonviable ne-
rotic and scarred territories, 31P-MRS demon-
trated complete absence of PCr (24,25). However,
onviable scar tissue results in a reduction in both
Cr and ATP, so the ratio cannot assess the degree
f loss of viable tissue. Measurement of absolute
oncentrations of high-energy phosphates has
hown that absolute myocardial ATP content was
ignificantly reduced in patients with fixed thallium
efects, i.e., nonviable scar tissue, but remained
onstant in those with viable myocardium (26).
lthough potentially valuable as a nonstress, non-
ontrast method for assessing myocardial viability,
gain, 31P-MRS is currently limited by its low
patial resolution.
Bottomley and Weiss (27) investigated and val-
dated the use of water suppressed 1H-MRS to
easure total myocardial creatine content in 10
atients with a history of myocardial infarction and
n an animal model of infarction after ligation of the
eft anterior descending coronary artery. They dem-
nstrated that creatine concentrations were sig-
ificantly lower in the infarcted myocardium of
atients compared with their noninfarcted myocar-
ium, and with healthy controls, and this was
onfirmed by biopsy studies in the animal model.
H-MRS has a higher sensitivity than 31P-MRS, so
t has a more realistic potential than 31P-MRS to
ecome a clinical tool to noninvasively identify
iable myocardium with intrinsic contrast.
Myocardial total 23Na signal is increased in both
cute necrosis and chronic myocardial scar, but not
n viable myocardium (28), so 23Na-magnetic res-
nance may provide another approach to investigat-
ng myocardial viability based on intrinsic contrast
Table 1). For example, in acute myocardial infarc-
ion patients, areas of increased 23Na signal inten-
ity have been shown to correlate with regional wall
otion abnormalities (29), and follow-up studies
ave demonstrated that the scar 23Na content
emains significantly increased in the long term
30). Although 23Na-magnetic resonance is a po-
entially exciting noninvasive method of assessing
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91yocardial viability, significant technical develop-
ents are needed to improve its spatial resolution.
One of the great strengths of MRS is that, in
rinciple, ischemic, scarred (nonviable), and hiber-
ating myocardium can be identified by a combi-
ation of 31P-, 23Na-, and 1H-MRS measurements
Table 1). Thus, if the technical hurdles can be
vercome, they would provide an attractive set of
ools to fully characterize myocardial tissue states in
oronary artery disease.
eart Failure and Transplantation
ltered cardiac energy metabolism is a characteris-
ic feature of heart failure (31). Clinical 31P-MRS
tudies have shown that PCr-to-ATP ratios de-
rease in advanced heart failure, but initially remain
ormal. These decreased PCr-to-ATP ratios in
atients with dilated cardiomyopathy correlate with
he New York Heart Association (NYHA) func-
ional class (32) and left ventricular ejection fraction
33), and they are a marker for prognosis: the
Cr-to-ATP ratio was a better predictor of long-
erm survival than NYHA functional class or left
entricular ejection fraction (34).
However, in heart failure, both PCr and ATP
ecrease in parallel, so PCr-to-ATP ratios cannot
etect the full extent of these changes. Using
bsolute quantification with the spectral localization
ith optimum pointspread function (SLOOP)
echnique, dilated cardiomyopathy patients showed
51% reduction in absolute PCr levels, a 35%
eduction in absolute ATP, and a 25% decrease in
Cr-to-ATP ratio (35). Therefore, PCr-to-ATP
atios underestimate the true extent of metabolic
erangement in heart failure.
The most sensitive indicators of deranged cardiac
nergetics in heart failure may be ATP turnover
ates. Weiss et al. (36) directly measured ATP flux
hrough the creatine kinase (CK) reaction in normal
nd failing human hearts using image-guided
-angle saturation transfer (FAST) 31P-MRS
uantification of CK flux. There was an 18%
eduction in cardiac PCr concentration in the heart
ailure patients compared with healthy controls,
ith no reduction in ATP levels. In contrast, ATP
urnover rates via CK were substantially reduced, by
0%, compared with those in healthy controls. This
roup has also shown that CK flux is reduced by
0% in hypertrophied hearts with maintained left
entricular function (37). These data illustrate that
easures of ATP turnover rates are the most iensitive indicators of energetic derangement in the
eart.
1H-MRS has also demonstrated significant re-
uctions in total creatine levels in dilated cardiomy-
pathy patients, which correlated with left ventric-
lar ejection fraction (38). Pharmacologic treatment
f heart failure with energy-sparing medications
uch as beta-blockers, angiotensin-converting en-
yme inhibitors, and angiotensin II receptor block-
rs improves outcome. In a small number of dilated
ardiomyopathy patients who were treated with
eta-blockers, angiotensin-converting enzyme in-
ibitors, diuretics, and digoxin for 3 months, PCr-
o-ATP ratios improved from 1.51  0.32 to 2.15
0.27 within 3 months in association with clinical
mprovement (Fig. 3) (32).
In a recent randomized, double-blind, cross-over
tudy, 12 heart failure patients, on conventional
herapy, were randomized to trimetazidine, a met-
bolic modulator partially inhibiting fatty acid oxi-
ation and stimulating glucose use, or placebo.
atients underwent physiological testing, echocar-
iography, and 31P-MRS (39). Trimetazidine im-
roved NYHA functional class and left ventricular
unction. Trimetazidine also resulted in a 33%
ignificant increase in PCr-to-ATP ratios, from
.35  0.33 to 1.80  0.50. Thus, trimetazidine
ppears to improve cardiac energetics in heart
ailure. This study also demonstrated that 31P-
RS can be used to monitor the energetic response
o heart failure treatment. However, this is a small
tudy with only 12 patients, and clearly, further
arge randomized trials of trimetazidine and other
etabolic modulators are required to reach defini-
ive conclusions.
Another interesting recent study showed that
atients with dilated cardiomyopathy can undergo a
ong-term exercise program without any detrimen-
al effects on cardiac energetics (40). Furthermore,
Table 1. Characterization of Ischemic, Scarred, or Stunned Myo
Using 31P, 1H, and 23Na Magnetic Resonance Spectroscopy
MRS Metabolite Ischemia
Scar
(Nonviable)
ATP (31P-MRS) 2 +
PCr (31P-MRS) 2 +
pHi (31P-MRS) 2 ↔
Na (23Na-MRS) 1 1
Total creatine (1H-MRS) ↔ +
Deoxymyoglobin (1H-MRS) 1 ↔
Reprinted, with permission, from Neubauer (64).
ATP  adenosine triphosphate; MRS  magnetic resonance spectroscopy.cardium
Stunned
↔
↔ or2
↔ or2
↔
↔
↔t is conceivable that the use of absolute changes in
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92Cr and ATP and of ATP turnover rates, as
urrogate markers for prognosis, in combination
ith functional assessment using CMR, will aid
rug trials in heart failure patients in the future.
Early identification of cardiac transplant rejection
s of paramount clinical importance to optimize and
arget appropriate medical therapy. Using 31P-
RS, PCr-to-ATP ratios have been shown to be
educed in both animal models (41) and patients
ith histologic signs of rejection, although no
orrelation was seen with biopsy scores (42). Exer-
ise 31P-MRS was investigated by Evanochko et al.
43), who showed a decrease in PCr-to-ATP ratios
uring exercise in some patients, although again,
istologic scores of rejection have not correlated
ith cardiac energetics. Further work is needed to
larify whether these techniques can be applied to
redict transplant rejection in patients (43).
alvular Heart Disease
atients with symptomatic heart failure from val-
ular heart disease (both aortic stenosis and mitral
egurgitation) have been shown to have reduced
Cr-to-ATP ratios in comparison with clinically
symptomatic patients. PCr-to-ATP ratios corre-
ated with left ventricular end-diastolic pressures
nd with end-diastolic wall stress in aortic stenosis
Figure 3. 31P Magnetic Resonance Spectroscopy in Heart Failure P
(Left) 31P-MRS (from top) volunteer, dilated cardiomyopathy (DCM)
DCM with severely reduced PCr-to-ATP ratio. (Right) Kaplan-Meier l
opathy. Patients were divided into two groups according to PCr-to-
ratio had an increased mortality over the study period compared w
from Neubauer et al. (34). Abbreviations as in Figure 2.nd left ventricular end-diastolic and end-systolic Miameter as well as left ventricular wall thickness
nd left atrial dimensions in mitral regurgitation
44–46). In a group of patients after aortic valve
urgery for aortic stenosis, 31P-MRS has been used
o follow the recovery of PCr-to-ATP ratios; these
mproved significantly from 1.28  0.17 to 1.47 
.14 9 months post-operatively (47). However, a
ong-term prospective study using cardiac MRS is
eeded to identify whether 31P-MRS can provide
nformation about the optimal timing of surgical
alve replacement.
nherited Cardiomyopathies
1P-MRS has the potential to noninvasively phe-
otype cardiomyopathies due to specific gene de-
ects such as hypertrophic cardiomyopathy (HCM).
CM is associated with myocardial energy deple-
ion secondary to inefficient force generation (48).
1P-MRS has demonstrated reduced PCr-to-ATP
atios in these patients, with a more pronounced
nergetic derangement in patients with a family
istory of HCM (49,50). Impaired PCr-to-ATP
atios have been demonstrated even in young
symptomatic patients, illustrating that the ener-
etic derangement occurs early in the disease pro-
ess (51).
Furthermore, future studies might enable 31P-
nts
h normal PCr-to-ATP ratio, DCM with reduced PCr-to-ATP ratio,
able analysis for total mortality of patients with dilated cardiomy-
ratios (1.60 and 1.60). Patients with a reduced PCr-to-ATP
hose with a higher ratio (p  0.036). Reprinted, with permission,atie
wit
ife t
ATP
ith tRS to phenotype different HCM genotypes from
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93Cr-to-ATP ratios at rest or in response to phys-
ologic and pharmacologic stress. The metabolic
esponses of patients, in combination with the
etailed anatomical, functional, and scar imaging
rovided by CMR, may identify prognostic indica-
ors that could aid in risk stratification and family
creening of relatives of HCM patients.
Patients and female carriers of Becker muscular
ystrophy with preserved left ventricular function
ave reduced PCr-to-ATP ratios in comparison
ith healthy volunteers (52). These findings may
rovide insight into the metabolic mechanisms of
ontractile failure and the development of cardio-
yopathy as well as identify targets and tools for
onitoring potential therapeutic intervention. Al-
ered cardiac energetics have also been identified in
atients with hereditary hemachromatosis (53) and
amilial hypercholesterolemia, in whom values nor-
alized after statin therapy (54).
iabetes, Obesity, and Diets
1P-MRS studies of patients with diabetes (both
ypes 1 and 2) and normal left ventricular ejection
raction have shown reduced PCr-to-ATP ratios,
hich correlate with increased plasma levels of free
atty acids and markers of diastolic function (Fig. 4)
Figure 4. Impaired Cardiac Energy Metabolism in Patients With
(Left) 31P MR spectra in a healthy control subject (top) and a patien
ATP ratio in the patient. (Right) Correlation of energetic derangeme
lated negatively with plasma free fatty acid concentrations for all su
concentration (r2  0.55, p  0.05) for the diabetic patients. Abbre
mann-Freestone et al. (55).55,56). These findings suggest a potential mecha-ism for the later development of cardiomyopathy
n this patient population.
A recent study by McGavock et al. (57) com-
ined 1H MRS and MR imaging in patients with
ype 2 diabetes mellitus, obesity, impaired glucose
olerance, and in lean normoglycemic individuals,
o investigate the relationship between cardiac ste-
tosis and the development of cardiomyopathy.
ardiac steatosis, detected by 1H-MRS was iden-
e 2 Diabetes
ith type 2 diabetes mellitus (bottom) showing reduced PCr-to-
ith fatty acid and glucose metabolism. PCr-to-ATP ratios corre-
cts (r2  0.32, p  0.01) and positively with plasma glucose
ons as in Figure 2. Reprinted, with permission, from Scheuer-
Figure 5. Improved Resolution of MRS Voxel Sizes With Increas
Strength: 1.5-T, 3-T, and 7-T
A schematic short-axis of the left ventricle and voxel position and s
1.5-, 3-, and 7-T. Figure is courtesy of Dr. Matthew Robson, OCMR, OTyp
t w
nt w
bje
viatiing Field
izes at
xford,United Kingdom. MRS  magnetic resonance spectroscopy.
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94ified in patients with impaired glucose tolerance,
ven before the development of type 2 diabetes mel-
itus. Early identification of such patients at risk may
nable therapeutic interventions to normalize myocar-
ial triglyceride metabolism and prevent the develop-
ent of diabetes and potential subsequent
ardiomyopathy.
Using a combination of 1H-MRS, 31P-MRS,
nd MR imaging, van der Meer et al. showed that
short-term, very low-calorie diet in healthy male
ubjects resulted in increased myocardial triglycer-
de levels and impaired diastolic function, with no
hange in myocardial PCr-to-ATP ratios (58).
hese data illustrate that the metabolic effects of
iet on the heart can be detected. MRS may provide
nsights into the early cardiac metabolic changes in
iabetes and obesity that may lead to cardiomyop-
thy and help identify potential therapeutic targets
o prevent pathological left ventricular remodelling.
uture Direction
he future of cardiac spectroscopy and its applica-
ion to clinical cardiology is reliant on a number of
echnical improvements. The greatest technical im-
rovements are expected from increased magnetic
eld strengths (3-T), which result in a linear
ncrease in signal to noise (59) and therefore allow
mprovements in spatial resolution, temporal reso-
ution, or both. Figure 5 shows an analysis of
mprovements in voxel sizes when field strength is
ncreased from 1.5- to 3- to 7-T, indicating that at
-T, we may finally be able to achieve proper
overage of the entire heart with a spatial resolution
orresponding to the American Heart Association
7-segment model (8 ml)—something currently
ot feasible at 1.5- or 3-T.
At these higher field strengths, it should also be
ossible to achieve substantially higher temporal
esolution, which will enable dynamic regional3. Bottomley PA. Noninvasive study of
high-energy phosphate metabolism in 2001;45:817–26.uring stress protocols in patients with ischemic
eart disease. In this way, biochemical ergometry
ay finally become a clinical reality.
Additional advances in coil design (e.g., phased
rray [60]) and sequence development (61) should also
ake significant contributions to improving resolu-
ion and reproducibility of human cardiac MRS.
Potentially the most advanced recent develop-
ents in MRS are efforts to massively increase the
RS signal by dynamic nuclear polarization (or
yperpolarization), which can boost the signal by a
actor of up to 100,000. At this point, the method
s entirely experimental where it has been shown to
uantify metabolic reactions such as Krebs cycle flux
62) and other metabolic pathways. Imaging of
ntracellular pH is another exciting new experimen-
al capability (63). Regulatory approval of hyperpo-
arized agents for use in humans and the short
alf-life of the enhanced signal (minutes) are major
urdles to be overcome.
onclusions
RS provides fundamental insights into cardiac
etabolism, and in particular, energetics, in cardiac
isease states as well as in response to therapeutic
ntervention, without the need for external tracers
r exposure to radiation (64,65). Although this tech-
ique is currently not yet used outside of the research
etting, with further technical developments leading to
mproved temporal and spatial resolution, cardiac
RS has the ability to dramatically advance our
nderstanding of the pathophysiology and metabolic
ature of a number of cardiac conditions, especially in
atients with heart failure, ischemic heart disease, and
nherited cardiomyopathies.
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